全国免费服务热线:021-64330607 服务时间 9:00-22:00 新浪微博 腾讯微博 注册 当前用户:[USERNAME],用户ID:[USERID] 用户中心 退出 收藏本页

clinical and experimental pharmacology and physiology

来源:作者:热度:Loading...日期:2014-01-24, 07:27 PM

期刊名称 clinical and experimental pharmacology and physiology

期刊缩写 CLIN EXP PHARMACOL P   
学科分类 医学 

出版周期 周刊   
审稿速度 6 个月 (平均) 

投稿命中率 20 % (均值)   
期刊主页 http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1440-1681   
ISSN 号 (printed): 0305-1870 (electronic): 1440-1681   
IF 趋势    2005      2006      2007      2008       2009     2010       2011      2012    
              1.437        1.78     2.038      2.196      1.936     1.96       1.851       2.16   
被收录情况  1. Science Citation Index 
                   2. Science Citation Index Expanded 
                   3. Current Contents - Life Sciences 
                   4. BIOSIS Previews   
PubSci评语 一审3个月左右,中稿率约20%。关注生理学和药理学。不容易命中,把握大的可以尝试。   
期刊简介 Clinical and Experimental Pharmacology and Physiology是在1974年由Mike Rand, Austin Doyle, John Coghlan and Paul Korner成立的国际期刊。重点关注生理学和药理学的前沿,强调基础研究向临床实践的转化。   
投稿注意事项 特别提醒:彩页免费。常规论文发表不收费,Open Access方式发表需要交纳3000美元出版费。
一般注意事项
1. ABOUT THE JOURNAL
SCOPE Clinical and Experimental            Pharmacology and Physiology provides a medium for the rapid online publication of original research papers, rapid communica-tions, and technical papers on the results of clinical and experimental work in pharma-cology and physiology. Reviews, research highlights and news/views are also published. 
The Journal aims to make a substantial  contribution to effective and productive communication between scientists   throughout the world who are working in these interrelated disciplines. Clinical and  Experimental Pharmacology and Physiology has been endorsed by the High Blood  Pressure Research Council of Australia (HBPRCA), the Australasian Society of Clinical and Experimental Pharmacologists and Toxi-cologists (ASCEPT) and the Australian Physio-logical Society (AuPS) (http://aups.org.au/).  
Editor-in-Chief 
Prof Jun-Ping Liu
Hangzhou Normal University, Institute of Ageing Research
 
Frequency 12 issues/year 
ISSN 0305-1870 (print), 1440-1681 (online)
Journal abbreviation  Clin. Exp. Pharmacol. Physiol.
When submitting your manuscript, please select the manuscript type that most closely fits with the topic of your paper. The  manuscript will be allocated to one  of the associate editors listed below, chosen by the Editor-in-Chief. Original Article-Other may be selected if your paper does not fall within one of these topics. 
Ageing: Xiang-Mei Chen
Cardiovascular-Vascular:     Grant Drummond 
Oxidative Stress: Reiko Inagi
Receptor signaling: Hui-Yao Lan
Neurobiology:  Jian-Sheng Lin
Kidney:  Akira Nishiyama
Epidemiology, Clinical Trials and 
   Public Health:  Christopher Reid
Hormones, Metabolisms, Diabetes, Obesity: John Speakman
Cancer: Dawei Xu
Drug discovery, Metabolism, Transport:    Shu-Feng Zhou
Contributors are invited to submit manu-scripts as Full Papers, Rapid Communications and Technical Papers. The content of these papers may be in any of the fields that are covered by the title Clinical and Experimental Pharmacology and Physiology, interpreted in the broadest sense. However, the Journal particularly welcomes papers within the broad subject of translational medicine and has a policy of not publishing papers describ-ing studies of the effects of impure natural substances. Experimental studies that pro-vide new mechanistic insights are given pri-ority over those that are largely descriptive. The submission of a paper must have no content that has been published or submit-ted for publication elsewhere, except as a brief abstract in the proceedings of a scien-tific meeting or symposium. Acceptance by Clinical and    Experimental Pharmacology and Physiology will preclude the publication of the material content elsewhere. 
2. PEER REVIEW
The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. In most cases, manuscripts are peer reviewed by at least two anonymous reviewers.   However, a  manuscript may be rejected without review. The content of the manuscripts will be held in strict confidence by the editors. The deci-sion to accept or reject rests with the Edi-tors.
All manuscripts should be written so that they are intelligible to the professional  reader who is not a specialist in the particu-lar field. They should be written in a clear,  concise, direct style. Where contributions  are judged as acceptable for publication on the basis of content, the Editor and the  Publisher reserve the right to modify  manuscripts to eliminate ambiguity and  repetition and improve communication  between author and reader. If extensive  alterations are required, the manuscript  will be returned to the author for revision.
3. MANUSCRIPT CATEGORIES
(1) EDITORIAL COMMENTARIES [BY INVITATION] Word Limit: 2000 words Abstract: No abstract References: Up to 10 Description: Proposals for Editorial        Commentaries may be submitted. However, in this case authors should only send an out-line of the proposed paper for initial consid-eration. 
(2) REVIEWS 
Word limit: 6000 words, including Title Page, Abstract, Text, References and Tables
Abstract: 250 words maximum
References: Up to 120 Figures/tables: Maximum 8. Description: Reviews are comprehensive analyses of specific topics. Proposals for re-views may be submitted with an outline of the proposed paper, the abstract and the author’s publication list for initial considera-tion. Both solicited and unsolicited review articles will undergo peer review prior to acceptance. 
(3) RESEARCH HIGHLIGHTS [BY INVITATION]  
Word Limit:  3000 words, including Title Page, Abstract, Text, References and Tables
Abstract:  250 words maximum
References:  Up to 80
Figures/Tables:  Maximum 4
Description: Research Highlights are invited on a particular topic and an editor is ap-pointed to oversee the peer    review pro-cess.  The manuscripts are        presented in the form of a mini-review.  Original data may be included, but if so,   sufficient detail on methods must be        provided so that prop-er peer review can be accomplished.  Further instructions are    provided upon invitation. 
(4) ORIGINAL  ARTICLES Word limit: 6000 words, including Title Page, Abstract, Text, References and Tables Abstract: 250 words maximum
References: Up to 60
Figures/tables: Maximum 8 Description: Full-length reports of current research in any of the fields covered by the title Clinical and Experimental Pharmacology and Physiology, interpreted in the broadest sense. The text should be arranged as  follows: Abstract, Introduction, Results, Dis-cussion, Methods, Acknowledgements,  References. Supporting information should be provided in a separate file.
The Editors are also willing to consider for publications of original articles that have been found not acceptable for publication by one of a small number of journals, on the basis of a perceived lack of priority rather than major flaws in scientific rigour. A full list of these journals, along with detailed instruc-tions for submission and information about the expedited review of such manuscripts, can be found at:  http://otis.wiley.com/otis/journal/overview/en/5446/CEP_new_pathway_papers.pdf  Articles should be submitted in their original form along with a copy of the decision letter from the journal. The decision letter should include at least two sets of reviewer com-ments. These manuscripts will then receive expedited review by the Editors.
(5) TECHNICAL PAPERS Word Limit: 6000 words, including Title Page, Abstract, Text, References and Tables. Abstract: 250 words maximum
References: Up to 60
Figures/tables: Maximum 8 Description: Technical Papers should be based mainly on the presentation of new techniques, or the testing or critique of  existing techniques. These should be  structured like Original Articles. 
 (6) RAPID COMMUNICATIONS 
Word limit: 3000 words (excluding             references) Abstract: maximum 250 words
Figures/ tables: 4 maximum  References: 60 maximum Description: Rapid Communications report most important new findings and are given priority by the Editorial Office. The text should include Abstract, Introduction, Re-sults, Discussion, Methods, Acknowledge-ments and References. Authors should indi-cate the reasons for Rapid publication.
(7) LETTERS TO THE EDITOR 
Word limit: 1200 words Abstract: 120 words  References: Up to 30 Figures/ tables: 2 maximum Description: Letters may be submitted to the Editor on any topic of short cutting edge research. Comments on papers recently pub-lished in CEPP will be welcomed. They should include  a brief summary and key words, but no subheadings. Name, postal address,          telephone, facsimile numbers and email ad-dresses of the corresponding author should be given on the title page.
Letters to the Editor are not  subjected to external peer-review, but will be reviewed by at least one editor or editori-al board member. Submissions may be edit-ed for length, grammatical  correctness, and journal style. Authors will be asked to approve editorial changes that alter the substance or tone of a letter or re-sponse. Letters that offer perspective on content already published in the Journal can use an arbitrary title, but a response from authors must cite the title of the first Letter: e.g.  Response to [title of Letter]. This ensures that readers can track the line of discussion. 
4. DISCLOSURE
Authors should declare any financial support or relationships that may pose a conflict of interest in the Covering Letter and in the manuscript under acknowledgements. If there is nothing to declare, a sentence should be included stating so.
5. ETHICAL CONSIDERATIONS
Investigations in human subjects must  conform to the International Ethical  Guidelines for Biomedical Research Involving Human Subjects (CIOMS/WHO: http://www.cioms.ch/). Consent must be obtained from each patient or subject after full explanation of the purpose, nature and risks of all procedures used, and the fact that such consent has been given should be     recorded in the paper. Patient anonymity should be observed. Experiments using animals must adhere to internationally accepted guidelines for the use of animals in research (e.g. CIOMS Guidelines) and the highest acceptable standard of ethical practice. Currently, these are the Australian Code of Practice for the Care and Use of Animals for Scientific Pur-poses. The Code is obtainable from the Sec-retary, NHMRC, PO Box 9848. Canberra, ACT 2601 Australia (http://www.nhmrc.gov.au/publications/synopses/ea16syn.htm
The alternative is to use the CIOMS Guide-lines (http://www.cioms.ch/).                      The purpose of the experiments must have been to obtain significant scientific infor-mation relevant to humans or other animals. Authors must declare, either in a covering letter or in the paper itself, whether or not prior approval for experiments was obtained from an animal experimentation ethics committee, animal care and use committee, equivalent committee or relevant body in the country of question. The name of the committee or relevant body must be includ-ed. Papers from countries where such com-mittees are not established, or if such evi-dence is not provided, must conform to the relevant Australian Guidelines. Currently these are Australian Code of Practice for  the Care and Use of Animals for Scientific Purposes. (http://www.nhmrc.gov.au/publications/synopses/ea16syn.htm).  Anaesthetic, analgesic or other measures taken to reduce or abolish any pain or discomfort must be detailed. If death or serious injury is used as an experi-mental end-point, the paper must indicate why such end-points were essential.  Neuromuscular blocking agents must not have been used without appropriate general anaesthesia, except in animals in which  sensory awareness had been eliminated. Techniques and procedures that minimize the use of live animals must have been
adopted where feasible and appropriate.  The statistical methods should have ensured the use of the minimum number of animals compatible with valid experimentation. Clinical and Experimental Pharmacology and Physiology retains the right to reject any manuscript on the basis of unethical conduct of either human or animal studies.
6. CLINICAL TRIALS REGISTRY
Registration in a public trials registry at or before the onset of patient enrolment is required. This policy applies to any clinical trial starting enrollment after January 1, 2006. For trials that began enrollment before this date, we request registration by April 1, 2006. We define a clinical trial as any re-search project that prospectively assigns human subjects to intervention or compari-son groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as studies on pharma-cokinetics or major toxicity (e.g. phase 1 tri-als), are exempt. We do not advocate one particular registry. The registry should meet the following  minimum criteria: (1) accessible to the public at no charge; (2) searchable by standard, electronic (Internet-based) methods; (3) open to all prospective registrants free of charge or at minimal cost; (4) validates  registered information; (5) identifies trials with a unique number; and (6) includes  information on the investigator(s), research question or hypothesis, methodology,  intervention and comparisons, eligibility  criteria, primary and secondary outcomes measured, date of registration, anticipated or actual start date, anticipated or actual date of last follow up, target number of  subjects, status (anticipated, ongoing or closed) and funding source(s).
Registries that currently meet these criteria include: (1) the registry sponsored by the United States National Library of Medicine (www.clinicaltrials.gov); (2) the International Standard Randomized Controlled Trial  Number Registry (http://www.controlled-trials.com); (3) the Australian Clinical Trials Registry (http://www.actr.org.au); (4) the Chinese Clinical Trials Register (http://www.chictr.org); and (5) the Clinical Trials Registry - India (http://www.ctri.in);  (6) University hospital Medical Information Network (UMIN) (http://www.umin.ac.jp/ctr/).
7. RANDOMIZED CONTROLLED TRIALS
Reporting of randomized controlled trials should follow the guidelines of The CONSORT Statement:  http://www.consort-statement.org
8. COPYRIGHT
Papers accepted for publication in Clinical and Experimental Pharmacology and  Physiology become copyright of John Wiley & Sons and authors will be asked to sign a transfer of copyright form. If your paper is accepted, the author identified as the formal corresponding author for the paper will re-ceive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.
For authors signing the copyright transfer agreement
If the OnlineOpen option is not selected the corresponding author will be presented with the copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be previewed in the samples associated with the Copyright FAQs below:
CTA Terms and Conditions http://authorservices.wiley.com/bauthor/faqs_copyright.asp
For authors choosing OnlineOpen
If the OnlineOpen option is selected the cor-responding author will have a choice of the following Creative Commons License Open Access Agreements (OAA):
- Creative Commons Attribution Non-Commercial License OAA

- Creative Commons Attribution Non-Commercial -NoDerivs License OAA


 
To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Ser-vices http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html
If you select the OnlineOpen option and your research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) you will be given the opportunity to publish your article under a CC-BY license supporting you in complying with Wellcome Trust and Research Councils UK require-ments. For more information on this policy and the Journal’s compliant self-archiving policy please visit: http://www.wiley.com/go/funderstatement
For RCUK and Wellcome Trust authors click on the link below to preview the terms and conditions of this license:
Creative Commons Attribution License OAA
To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Ser-vices http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html
NIH Public Access Mandate For those  interested in our policy on the NIH Public Access Mandate, please consult our  policy statement: http://www.wiley.com/WileyCDA/Section/id-321171.html.
9. STYLE OF MANUSCRIPTS
Manuscripts should follow the style of  the Vancouver agreement detailed in the Uniform Requirements for Manuscripts  Submitted to Biomedical Journals, as  presented in JAMA 1997; 277: 927-34.
References are in Vancouver style. For  further details regarding reference style, please see Section 10. 
Spelling The Journal uses UK spelling and authors should follow the latest edition of the Oxford Concise English Dictionary. 
Footnotes: Footnotes arising from the text must not be used.
Standard abbreviations: These should be used sparingly. They should be defined in the Summary and on the first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the  abbreviation is helpful to the reader.
Units of measurement: As far as possible, these should conform to the SI conventions, with the notable exception that blood  pressures should be given in mmHg. It is strongly recommended that contributors consult the booklet Units, Symbols and  Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. D. N.  Baron), 1988, The Royal Society of Medicine Services, London. The recommendations outlined therein will be followed. 
Methods of statistical analysis: The journal recommends that investigators seek the  advice of a professional biostatistician in the design stage of their study, as well as during the stage of actual data analysis. Statistical
methods used should be identified, with  appropriate citation of statistical texts or articles that describe their use. Reasons for choosing particular methods of analysis, and for the number of experimental units, should be stated. The name and source of         commercial statistical computer packages used should be identified. The statistical  section should contain sufficient detail for the reader to have a clear idea about how the analysis was performed. The level of  statistical significance (alpha) should be   defined and it should be stated explicitly whether this refers to one- or two-sided probability.    Nevertheless, exact P values should be given to a sensible number of   significant figures (e.g. P = 0.01 rather than   P = 0.0058). The risk of type 1 error (a false positive inference) should always be con-trolled. This requires the use of global statis-tical tests of significance where possible, particularly in experimental designs that involve repeated measurements in the same experimental units (humans, animals, tissues or cells). Multiple comparisons within a sin-gle experiment should only be made when this is absolutely necessary and, if so,  P values should be conservatively corrected to control the risk of type 1 error. Two tech-niques that provide excellent control of the type 1 error rate are the 'false discovery rate' procedure (Curran-Everett D, Benos DJ. Guidelines for reporting statistics in journals published by the American Physiological  Society. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004; 287: R247-9) and the Ryan-Holm stepdown Bonferroni procedure (Lud-brook J. Multiple comparison procedures updated. Clin. Exp. Pharmacol. Physiol. 1998; 25: 1032-7). Confidence intervals may be used in addition to P values.
Data should be expressed as mean (SD) when the intention is to indicate the degree of  variability of the data around the mean  value, and as mean ± SEM when the inten-tion is to estimate the population mean from the sample data. In either case, the numbers of observations (n) should be stipulated. This allows the reader to calculate SD from SEM and vice versa. (For further reading, see  Ludbrook J. Comments on journal guidelines for reporting statistics. Clin. Exp. Pharmacol. Physiol. 2005; 32: 324-6 (Letter).)
Detailed guidelines on the use and presenta-tion of statistics in Clin. Exp. Pharmacol.  Physiol. can be found online at: http://otis.wiley.com/otis/journal/overview/en/5446/CEPP_Guidelines_for_the_Use_and_Presentation_of_Statistics.pdf  
Chemical substances: These must be     properly identified. Except for standard   laboratory chemicals, the source of supply must be given. Drug nomenclature should follow the rules of the International Union of Pharmacology Committee on Receptor    Nomenclature and Drug Classification, pub-lished in various articles in Pharmacological Reviews. Proprietary names should be   avoided unless the paper is concerned with a specific formulated product, in which case the nature of the formulation should be stat-ed. Isotopically labelled chemicals should be identified by the atomic number and   sym-bol of the isotope, its location in the         molecule and the specific activity in standard (SI) units.
Receptors: For receptor types,  nomenclature should also follow the  conventions established by the IUPHAR Committee on Receptor Nomenclature and Drug Classification (International Union of Basic and Clinical Pharmacology), which are published in Pharmacological Reviews.
10. STRUCTURE OF MANUSCRIPTS The length of manuscripts should adhere  to the specifications under the section  Manuscript Categories.                                Manuscripts should be presented in the  following order: (i) Title Page, (ii) Abstract, (iii) Introduction, (iv) Results,  (v) Discussion, (vi) Methods, (vii) Acknowl-edgements (including disclosure), (viii) Ref-erences, (ix) tables (each table complete with title and footnotes), (x) figure legends and (xi) figure.  Supporting Information should be supplied as a supplementary  file. 
TITLE PAGE
The first page of the manuscript should  contain the following information: 
Title: The title should be as informative  as possible but should avoid over-detailed information about the experimental          procedures.  Titles should not exceed 250 characters (including spaces).
Family name for each author, preceded by initial(s) or given name(s): That part of each family name which is to appear in indexes must be underlined. In keeping with the  latest guidelines of the International  Committee of Medical Journal Editors,  each author's contribution to the paper is  to be quantified in the covering letter.
Laboratory or Institute: The official name  (in English) of each place in which the work reported in the manuscript was carried out should be given, together with the larger organization (if applicable), city, state (if  applicable) and country.
Short title: This will be used as a running heading in the printed text; it must not  exceed a total of 45 characters (including spaces) and should be as informative as  possible within this limit. Abbreviations should be avoided if possible.
Author for correspondence: The name and full postal address, facsimile, telephone  and email details of the corresponding  author must be provided and clearly  identified. All correspondence regarding  the manuscripts, proofs and requests for reprints will be sent to this author, using  the contact details provided. 
Present addresses of authors: Should the addresses of other authors differ from  that of the author for correspondence,  this information should be provided and  will be published.
ABSTRACT
This should commence on page two and  consist of a continuous paragraph, describing the aim of the study, what was done, the main findings and the conclusions reached.  A limit of 250 words will apply.
Key words: These are required for indexing the content of the paper, and should, if  possible, be selected from the US National Library of Medicine's 'Medical Subject  Headings' (MeSH) browser list (http://www.nlm.nih.gov/mesh/meshhome.html). A maximum of 10 words or phrases should be sufficient. Key words should be arranged in alphabetical order. 
INTRODUCTION
This section should commence on a new page and contain a concise statement of  the reason for doing the work, and should not contain a major statement about either the findings or the conclusions.
RESULTS
The findings should be presented clearly with adequate reference to figures and tables. The text of Results and the information con-tained in figures and tables should comple-ment one another; repetitive presentation of the same data should be avoided. Material appropriate to Discussion should not be in-cluded in Results. However, brief comments on minor points are acceptable if they help  to consolidate the new information being presented or if they assist the reader to  follow the progression of ideas in moving from one set of data to another.
METHODS
Sufficient information should be given to permit the work to be repeated in other  clinics or laboratories. 
 
 
 
DISCUSSION
This should not be a mere reiteration of the Results. It should deal with the relationship of the new information given in Results to the corpus of knowledge in that field, and should be pertinent to the data presented. The main conclusions should be incorporated in the final paragraph.
ACKNOWLEDGEMENTS
The source of financial grants and other funding must be acknowledged, including a frank declaration of the authors’ industrial links and affiliations. The contribution of colleagues or institutions should also be  acknowledged. Thanks to anonymous  reviewers are not appropriate. 
REFERENCES
Must follow the Vancouver style and should be numbered and listed in order of appear-ance in the text. In the reference list, cite  the names of all authors when there are six or fewer; when seven or more, list the first three followed by et al. Names of journals should be abbreviated in the style used in Index Medicus. Reference to unpublished data and personal communications should appear in the text only.
References should be set out as follows:
Standard journal article 1. Hoka S, Takeshita A, Yamamoto K, Ito N. Effects of high salt intake on control of hindlimb vascular resistance by arterial baro-reflex and vagal afferents in spontaneously hypertensive rats. Clin. Exp. Pharmacol. Phys-iol. 1993; 20: 663-9.
Books and other monographs 2. Dale MM, Forman JC, Fan TP. Textbook of Immunopharmacology, 3rd edn. Blackwell Science, Oxford. 1993.
Chapter in a book 3. Williams AJ. Potassium channel openers: Clinical aspects. In: Weston AH, Hamilton TC (eds). Potassium Channel Modulators. Blackwell Science, Oxford. 1992; Ch. 17.
Titles of papers and books are to be given in the original language of publication.
Electronic material 4. Bartoszewski S, Gibson JB. Injecting un-dechorionated eggs under ethanol. Drosophi-la Inform. Newslett. 1994; 14 (online). Fly-base: http://morgan.harvard.edu/fb.html
5. Gonen T, Grey AC, Jacobs MD, Donaldson PJ, Kistler J. MP20, the second most abun-dant lens membrane protein and member of the tetraspanin superfamily, joins the list of ligands of galectin-3. BMC Cell Biol. 2001; 17: Epub 14 August 2001; doi:10.1186/1471-2121-2-17
TABLES
Tables should be self-contained and        complement but not duplicate information in the text. Tables should be numbered        consecutively in Arabic numerals. Each table should be presented on a separate page with a comprehensive but concise legend above the table. Tables should be double-spaced and vertical lines should not be used to    separate columns. Column headings should be brief, with units of measurement in     parentheses; all abbreviations should be    defined in footnotes. Footnote symbols: ., ., § should be used (in that order) and *, **, *** should be reserved for P values. The  table and its legend/footnotes should be understandable without reference to the text. 
FIGURES
All illustrations (line drawings and photo-graphs) are classified as figures. Figures should be cited in consecutive order in the text. Magnifications should be indicated  using a scale bar on the illustration. If figures have been reproduced from another source, a letter from the copyright holder (usually the Publisher), stating authorization to  reproduce the material, must be attached  to the covering letter.
Size Figures will be greatly reduced in size for publication. Therefore, fonts must be large and consistent and lines should be relatively thick. Authors should prepare figures to fit within the column (84 mm), or the full text width (176 mm).                                           Resolution Figures must be supplied as high resolution saved as .eps or .tif. 
Halftone figures: 300 dpi (dots per inch)
Colour figures: 300 dpi saved as CMYK
Figures containing text:  400 dpi
Line figures: 1000 dpi
Color figures Files should be set up as CMYK (cyan, magenta, yellow, black) and not as RGB (red, green, blue) so that colors as they appear on screen will be a closer               representation of how they will print in the Journal. There is no fee for colour             publication.
Line figures Must be sharp, black and white or colour graphs or diagrams, drawn         professionally or with a computer graphics package. 
Text sizing in figures Lettering must be in-cluded and should be sized at approximately 8 point in the printed journal. Line width should be between 0.5 and 1 point. Authors are asked to keep in mind that their figures will be reduced in size for print publication.  It is the author’s responsibility to ensure  that figure lines and labels are legible when reduced.
Figure legends Type figure legends on a sep-arate page. Legends should be concise but comprehensive. The figure and legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement. More help on prepa-ration of illustrations can be found at:  http://otis.wiley.com/otis/journal/overview/en/5446/CEPP_Guidelines_for_Preparation_and_Submission_of_Figures.pdf 
EQUATIONS
Equations should be numbered sequentially with Arabic numerals; these should be ranged right in parentheses. All variables should appear in italics. Use the simplest possible form for all mathematical symbols.
11. SUPPORTING INFORMATION
Supporting Information is provided by the authors to support the content of an article but is not integral to that article. It should be submitted as a supplementary  file or files. This information will be accessible from the   journal’s online Table of Contents in a file or files linked to the article itself. Supporting Information must be submitted together with the article for review; it should not be added at a later stage. It can be in the form of text, tables, figures, appendices and even video footage. Reference to Supporting   Information in the main body of the article is allowed. However, it should be noted that excessive reference to a piece of Supporting Information may indicate that it would be better suited as a proper reference or fully included figure/table. The materials will be published as they are supplied and will not  be checked or typeset in any way. All Sup-porting Information files should come with a legend, listed at the end of the main article. Each figure and table file should not be larg-er than 5MB, although video files may be larger. Prior to submission, please check the     guidelines at: http://authorservices.wiley.com/bauthor/suppmat.asp 
 
12. SUBMISSION OF MANUSCRIPTS
Manuscripts must be submitted online at:  http://mc.manuscriptcentral.com/cepp
Email addresses must be supplied for  corresponding authors and all co-authors,  as all correspondence will be by email.
GENERAL
All articles submitted to the Journal must comply with these instructions. Failure to do so will result in return of the manuscript and possible delay in publication.
. Text  must be double-spaced.

. All margins should be at least 30 mm.

. All pages should be numbered consecu-tively in the top right-hand corner,  beginning with the title page.

. Do not use ‘Enter’ at the end of lines within a paragraph.

. Turn the hyphenation option off; include only those hyphens that are essential to the meaning.

. Specify any special characters used to represent non-keyboard characters.

. Take care not to use l (ell) for 1 (one),  O (capital o) for 0 (zero) or . (German esszett) for β (Greek beta).

. Use a tab, not spaces, to separate data points in tables. If you use a table editor function, ensure that each data point is contained within a unique cell (i.e. do  not use carriage returns within cells).

. Each figure should be supplied as a  separate file, with the figure number  incorporated in the file name.  The figure itself must also be numbered.   


COVER LETTER
Papers are accepted for publication in  the Journal on the understanding that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium. This must be stated in the cover letter.
The cover letter must also contain an  acknowledgement that all authors have  contributed significantly to the work, and that all authors are in agreement with the content of the manuscript. In keeping with the latest guidelines of the International Committee of Medical Journal Editors, each author’s contribution to the paper is to be quantified.
Authors must also state that the protocol  for the research project has been approved by a suitably constituted Ethics Committee of the institution within which the work was undertaken and that it conforms to the  provisions of the Declaration of Helsinki in 1995 (as revised in Edinburgh 2000). All  investigations on human subjects must  include a statement that the subject gave informed consent and patient anonymity should be preserved. Authors should declare any financial support or relationships that may pose conflict of interest. 
 
 
PRE-SUBMISSION ENGLISH-LANGUAGE EDITING
Authors for whom English is a second       language may choose to have their        man-uscript professionally edited before submis-sion to improve the English. A list of inde-pendent suppliers of editing services can be found at http://authorservices.wiley.com/bauthor/english_language.asp. All services are paid for and arranged by the author, and the use of one of these services does not guarantee acceptance or preference for  publication.
13. PROOFS
It is essential that corresponding authors supply an email address to which               correspondence can be emailed while their article is in production. Notification of the URL from where to download a Portable Document Format (PDF) typeset page proof, associated forms and further instructions will be sent by email to the corresponding      author. The   purpose of the PDF proof is a final check of the layout, and of tables and figures. Alterations other than the essential          correction of errors are unacceptable at PDF proof stage. The proof should be checked, and approval to publish the article should be emailed to the Publisher by the date indicat-ed, otherwise, it may be signed off by the Editor or held over to the next issue. Acrobat Reader will be required in order to read the PDF. This   software can be downloaded (free of charge) from the following Web site: http://www.adobe.com/products/acrobat/readstep2.html  This will enable the file to be opened, read on screen, and printed out in order for any corrections to be added. Further instructions will be sent with the proof.
14. OFFPRINTS
A free PDF will be supplied to the  corresponding author. A minimum of 50  offprints will be provided upon request, at the author's expense. These paper offprints may be ordered online. Please visit http://offprint.cosprinters.com/, fill in the necessary details and ensure that you type information in all the required fields. If you have any queries about offprints, please email offprint@cosprinters.com
15. TRACKING MANUSCRIPTS
1) BEFORE ACCEPTANCE During the review process authors can track their manuscript  through their Author Cen-tre at:  http://mc.manuscriptcentral.com/CEPP
2) AFTER ACCEPTANCE Author Services enables authors to track their article, once it has been accepted, through the production process to publica-tion online and in print. Authors can check the status of their articles online and choose to receive automated emails at key stages of production so they do not need to contact the Production Editor to check on progress. For more details on online production    tracking and for a wealth of resources,     including FAQs and tips on article             preparation, submission and more, visit: http://authorservices.wiley.com/ 
16. ACCEPTED ARTICLES
Accepted Articles is a Wiley-Blackwell service whereby peer-reviewed accepted articles are published online, prior to their ultimate in-clusion in a print or online issue. Articles published within Accepted Articles have been fully refereed, but have not been through the copy-editing, typesetting and proof correction process. This process en-sures that accepted articles are

扫描二维码
关注Pubsci微信
微信公共账号:pubsci888

关键词:论文翻译润色,论文评估,SCI投稿,SCI期刊发表,医生出国进修